The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Just over a year after striking an obesity deal with Novo Nordisk, an SEC filing shows Flagship Pioneering spinout Omega Therapeutics is days away from bankruptcy and will lay off up to 17 employees.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Some countries are more obese than others. For example, around 4.5% of the adult population in Japan belongs to this category ...

Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...

When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back ...

In a few short years, excitement about groundbreaking anti-obesity drugs made Novo Nordisk ... the market will be worth the $100bn plus by the end of the decade that analysts predict.

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Of the nearly 500 readers who responded to our poll, the majority (70%) said they wouldn't support a tax on sugary drinks.

Alison Field traced her early insights into obesity and eating disorders to a ... Their marriage was “the only decision that matters in the end. I was the lucky guy.” Dr. Field was tenacious ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...